PMID- 35990634
OWN - NLM
STAT- MEDLINE
DCOM- 20220823
LR  - 20220824
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 13
DP  - 2022
TI  - Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic 
      arterial infusion chemotherapy for advanced hepatocellular carcinoma.
PG  - 929141
LID - 10.3389/fimmu.2022.929141 [doi]
LID - 929141
AB  - BACKGROUND: Atezolizumab plus bevacizumab has been proved to have promising 
      antitumor activity and tolerable safety in patients with unresectable 
      hepatocellular carcinoma (HCC). Hepatic arterial infusion chemotherapy (HAIC) 
      also demonstrated high response rates and favorable survival for patients with 
      advanced HCC. This study aimed to explore the preliminary clinical efficacy and 
      safety of atezolizumab plus bevacizumab combined with HAIC for patients with 
      treatment-naive advanced HCC. METHODS: Between October 2020 and September 2021, 
      patients with advanced HCC who initially received atezolizumab plus bevacizumab 
      combined with HAIC of oxaliplatin, fluorouracil, and leucovorin (FOLFOX) from 
      three hospitals in China were reviewed for eligibility. The efficacy was 
      evaluated by tumor response rate and survival, and the safety was evaluated by 
      the frequency of key adverse events (AEs). RESULTS: In total, 52 eligible 
      patients with advanced HCC who received triple therapy were included in this 
      study. The objective response rates (ORRs) based on mRECIST and RECIST1.1 
      criteria were 67.3% and 44.2%, respectively. The median progression-free survival 
      (PFS) of patients was 10.6 months (95% CI, 8.37-13.8), and the overall survival 
      (OS) was not reached. Extrahepatic metastasis was an independent risk factor 
      associated with PFS. All AEs were controlled and no treatment-related deaths 
      occurred. CONCLUSION: Atezolizumab plus bevacizumab combined with HAIC-FOLFOX had 
      a significant therapeutic effect and manageable AEs in patients with advanced 
      HCC, which may be a potential treatment option for advanced HCC.
CI  - Copyright (c) 2022 Xin, Cao, Yang, Zhang, Chen, Cao, Zhou, Li and Zhou.
FAU - Xin, Yujing
AU  - Xin Y
AD  - Department of Interventional Therapy, National Cancer Center/National Clinical 
      Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences 
      and Peking Union Medical College, Beijing, China.
FAU - Cao, Fei
AU  - Cao F
AD  - Department of Interventional Radiology, The Cancer Hospital of the University of 
      Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic 
      Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, China.
FAU - Yang, Hongcai
AU  - Yang H
AD  - Department of Interventional Therapy, National Cancer Center/National Clinical 
      Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences 
      and Peking Union Medical College, Beijing, China.
FAU - Zhang, Xinyuan
AU  - Zhang X
AD  - Department of Interventional Therapy, National Cancer Center/National Clinical 
      Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences 
      and Peking Union Medical College, Beijing, China.
FAU - Chen, Yi
AU  - Chen Y
AD  - Department of Interventional Therapy, National Cancer Center/National Clinical 
      Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences 
      and Peking Union Medical College, Beijing, China.
FAU - Cao, Xiaojing
AU  - Cao X
AD  - Department of Interventional Therapy, National Cancer Center/National Clinical 
      Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences 
      and Peking Union Medical College, Beijing, China.
FAU - Zhou, Xiang
AU  - Zhou X
AD  - Department of Interventional Therapy, National Cancer Center/National Clinical 
      Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences 
      and Peking Union Medical College, Beijing, China.
FAU - Li, Xiao
AU  - Li X
AD  - Department of Interventional Therapy, National Cancer Center/National Clinical 
      Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences 
      and Peking Union Medical College, Beijing, China.
FAU - Zhou, Jinxue
AU  - Zhou J
AD  - Department of Hepatobiliary and Pancreatic Surgery, Affiliated Cancer Hospital of 
      Zhengzhou University, Zhengzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20220805
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 2S9ZZM9Q9V (Bevacizumab)
RN  - 52CMI0WC3Y (atezolizumab)
SB  - IM
MH  - Antibodies, Monoclonal, Humanized
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects
MH  - Bevacizumab/adverse effects
MH  - *Carcinoma, Hepatocellular/pathology
MH  - Humans
MH  - *Liver Neoplasms/pathology
PMC - PMC9388744
OTO - NOTNLM
OT  - FOLFOX
OT  - advanced hepatocellular carcinoma
OT  - atezolizumab
OT  - bevacizumab
OT  - hepatic arterial infusion chemotherapy
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/08/23 06:00
MHDA- 2022/08/24 06:00
PMCR- 2022/01/01
CRDT- 2022/08/22 03:58
PHST- 2022/04/26 00:00 [received]
PHST- 2022/07/08 00:00 [accepted]
PHST- 2022/08/22 03:58 [entrez]
PHST- 2022/08/23 06:00 [pubmed]
PHST- 2022/08/24 06:00 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2022.929141 [doi]
PST - epublish
SO  - Front Immunol. 2022 Aug 5;13:929141. doi: 10.3389/fimmu.2022.929141. eCollection 
      2022.